Fishman Jay A Ltd. MI Has $4.03 Million Holdings in Johnson & Johnson (NYSE:JNJ)

Fishman Jay A Ltd. MI reduced its position in Johnson & Johnson (NYSE:JNJ) by 17.4% in the 4th quarter, Holdings Channel reports. The firm owned 27,844 shares of the company’s stock after selling 5,883 shares during the quarter. Fishman Jay A Ltd. MI’s holdings in Johnson & Johnson were worth $4,027,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently bought and sold shares of the company. Augustine Asset Management Inc. raised its holdings in shares of Johnson & Johnson by 13.9% in the 4th quarter. Augustine Asset Management Inc. now owns 3,505 shares of the company’s stock worth $507,000 after buying an additional 427 shares in the last quarter. Cardinal Strategic Wealth Guidance lifted its holdings in shares of Johnson & Johnson by 23.8% during the fourth quarter. Cardinal Strategic Wealth Guidance now owns 4,662 shares of the company’s stock valued at $674,000 after acquiring an additional 895 shares during the period. Community Bank & Trust Waco Texas boosted its stake in shares of Johnson & Johnson by 1.7% in the 4th quarter. Community Bank & Trust Waco Texas now owns 55,135 shares of the company’s stock valued at $7,974,000 after purchasing an additional 944 shares in the last quarter. Wealthcare Capital Partners LLC acquired a new stake in shares of Johnson & Johnson during the 4th quarter worth about $480,000. Finally, Sovran Advisors LLC bought a new position in Johnson & Johnson during the 4th quarter valued at about $3,288,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Price Performance

Shares of JNJ opened at $156.20 on Friday. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45. The stock has a market cap of $376.08 billion, a P/E ratio of 23.49, a price-to-earnings-growth ratio of 2.46 and a beta of 0.52. The stock’s 50-day moving average price is $147.73 and its two-hundred day moving average price is $156.01. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $168.85.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, beating the consensus estimate of $1.99 by $0.05. The firm had revenue of $22.52 billion during the quarter, compared to the consensus estimate of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.35%. The business’s quarterly revenue was up 5.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.29 earnings per share. On average, equities analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be paid a $1.24 dividend. The ex-dividend date is Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a yield of 3.18%. Johnson & Johnson’s payout ratio is 74.59%.

Insiders Place Their Bets

In other Johnson & Johnson news, Director Mark A. Weinberger bought 1,000 shares of the stock in a transaction that occurred on Thursday, December 12th. The stock was acquired at an average cost of $147.22 per share, with a total value of $147,220.00. Following the purchase, the director now owns 1,000 shares in the company, valued at $147,220. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 0.16% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the stock. Barclays raised their price objective on shares of Johnson & Johnson from $159.00 to $166.00 and gave the stock an “equal weight” rating in a report on Tuesday, January 28th. Raymond James reduced their price objective on Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating on the stock in a research note on Thursday, January 23rd. Argus raised Johnson & Johnson to a “strong-buy” rating in a report on Friday, January 24th. Guggenheim increased their price objective on shares of Johnson & Johnson from $162.00 to $166.00 and gave the stock a “neutral” rating in a report on Monday, February 3rd. Finally, Leerink Partners dropped their target price on shares of Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating for the company in a research note on Thursday, January 23rd. Nine equities research analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $170.67.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.